On remand from the 4th Circuit, a West Virginia federal court finds the city and Cabell County failed to prove unreasonable conduct or causation on their public nuisance claim.
U.S. District Court for the Southern District of West Virginia | No. 3:17-01362 | Amended Findings of Fact and Conclusions of Law dated Nov. 18, 2026
A federal judge in West Virginia has again entered judgment for three drug distributors in a public nuisance lawsuit over the opioid epidemic, concluding on remand that the City of Huntington and the Cabell County Commission did not prove the companies acted unreasonably or caused the harm alleged.
Senior U.S. District Judge David A. Faber of the U.S. District Court for the Southern District of West Virginia issued amended findings of fact and conclusions of law Nov. 18 in City of Huntington v. AmerisourceBergen Drug Corp., No. 3:17-01362, and Cabell County Commission v. AmerisourceBergen Drug Corp., No. 3:17-01665. The defendants are AmerisourceBergen Drug Corp., Cardinal Health Inc. and McKesson Corp.
The decision follows an Oct. 28, 2025, ruling by the 4th U.S. Circuit Court of Appeals that vacated Faber’s 2022 judgment for the distributors.
Procedural history
The local governments proceeded on a single public nuisance claim. According to the opinion, they contend the distributors’ wholesale distribution of prescription opioids in Huntington and Cabell County created an opioid epidemic there, and they seek only abatement, having waived damages.
After a bench trial held from May 3 through July 12, 2021, Faber ruled for the distributors on July 4, 2022. He predicted West Virginia would not extend public nuisance law to opioid distribution and concluded, alternatively, that the plaintiffs had not proved a nuisance.
The 4th Circuit certified the state-law question to the Supreme Court of Appeals of West Virginia, which declined to answer. The appeals court then held that opioid distribution “may qualify as a public nuisance” under West Virginia law, that Faber had misconstrued distributors’ duties under the Controlled Substances Act, and that abatement may include money to fund remediation. According to the 4th Circuit’s published opinion, Senior Judge Barbara Milano Keenan wrote for the panel, joined by Judges King and Benjamin.
Faber wrote that he is bound by the 4th Circuit’s prediction. The court heard oral argument May 28.
Compliance and reasonableness
Applying the standard the appeals court identified, Faber found the distributors “substantially complied with their obligations” under the act to develop and implement suspicious order monitoring systems that examined individual pharmacy orders for signs of diversion. Their conduct was therefore not unlawful, he concluded. In a footnote, he wrote that his 2022 decision had also recognized the duty to operate a system to disclose suspicious orders.
The opinion takes up evidence the 4th Circuit had flagged. On the low number of orders reported to the Drug Enforcement Administration as suspicious, Faber cited trial testimony from former DEA official Joseph Rannazzisi that the number of such reports should be small. He found that a former McKesson regulatory affairs director’s 2011 email, read in full, did not support an inference that threshold increases were close to automatic. And he rejected the plaintiffs’ argument about high-volume doctors a plaintiffs’ expert labeled “outlier” prescribers, finding no showing that the distributors knew of any illegal prescribing by them.
Turning to a balancing test, Faber acknowledged the dangers of opioids but concluded that distributing medicine to meet “the legitimate medical needs of patients as determined by doctors exercising their medical judgment in good faith cannot be deemed an unreasonable interference with a right common to the general public.”
Causation
Faber separately concluded the plaintiffs proved neither but-for nor proximate causation. He found that doctors, most of them acting in good faith under an evolving standard of care for treating pain, determined the volume of prescription opioids that pharmacies ordered, and that the plaintiffs presented no evidence of diversion by the distributors’ pharmacy customers in Huntington or Cabell County.
He also concluded that three “intervening acts” would break any causal chain: independent prescribing decisions by doctors, independent dispensing decisions by pharmacists and independent decisions by individuals who abused prescription and illegal opioids.
The opinion does not dispute the epidemic’s toll. It finds 1,151 overdose deaths in Cabell County from 2001 to 2018, of which 1,002 were opioid-related, and that the three companies distributed 51,349,150 dosage units of oxycodone and hydrocodone to retail pharmacies in the two jurisdictions between 2006 and 2014.
“But how can it be unreasonable for a wholesale distributor of opioids to fulfill bulk orders for opioids that are used to fill prescriptions written by doctors in good faith?” Faber wrote.
Alternative abatement analysis
Although he held the plaintiffs are entitled to no relief, Faber evaluated their proposed 15-year abatement plan, priced by their expert at $2,544,446,548 in future dollars, to avoid a second remand if the 4th Circuit disagrees. That analysis is not necessary to the judgment.
Following the approach used by the multidistrict litigation court in Ohio cases against pharmacies, a ruling the 6th Circuit has since vacated, Faber struck components he found insufficiently directed at treatment and prevention, reducing the plan to $1,757,849,623. He applied a 25% reduction for costs attributable solely to illicit, non-prescription opioids and allocated 25% of the remainder to the three distributors, citing the roles of manufacturers, dispensers and physicians.
The distributors’ share of any abatement remedy “should be limited to $329,596,804,” he wrote, adding that unused funds should not revert to the plaintiffs. He also wrote that any lump-sum award should be reduced to present value.
Takeaways
- The judgment again favors AmerisourceBergen, Cardinal Health and McKesson. Faber accepted as binding the 4th Circuit’s prediction that opioid distribution can be a public nuisance under West Virginia law, but found the claim failed on the trial record.
- The ruling rests on separate grounds: the plaintiffs did not prove an unreasonable interference with a public right, and they did not prove but-for or proximate causation. The opinion treats both as questions of fact decided after a bench trial.
- The $329,596,804 figure is an alternative calculation, not an award. It would matter only if the distributors are later found liable.
- Analysis: The opinion responds point by point to evidence the 4th Circuit directed the district court to consider, including threshold increases, suspicious order reporting and outlier prescribers.
Read the full opinions: City of Huntington v. AmerisourceBergen Drug Corp., No. 3:17-01362 — S.D. W. Va. Amended Findings of Fact and Conclusions of Law (Nov. 18, 2026) and City of Huntington v. AmerisourceBergen Drug Corp., Nos. 22-1819, 22-1822 — 4th Cir. Opinion (Oct. 28, 2025).

